Aberrant forms of the anaplastic lymphoma kinase (ALK) have been implicated in the pathogenesis of multiple human cancers, where ALK represents a rational therapeutic target in these settings. In this study, we report the identification and biological characterization of X-376 and X-396, two potent and highly specific ALK small molecule tyrosine kinase inhibitors (TKIs). In Ambit kinome screens, cell growth inhibition studies, and surrogate kinase assays, X-376 and X-396 were more potent inhibitors of ALK but less potent inhibitors of MET compared to PF-02341066 (PF-1066), an ALK/MET dual TKI currently in clinical trials. Both X-376 and X-396 displayed potent anti-tumor activity in vivo with favorable pharmacokinetic and toxicity profiles. Similar levels of drug sensitivity were displayed by the three most common ALK fusion proteins in lung cancer (EML4-ALK variants E13;A20, E20;A20, and E6b;A20) as well as a KIF5B-ALK fusion protein. Moreover, X-396 could potently inhibit ALK kinases engineered with two point mutations associated with acquired resistance to PF-1066, L1196M and C1156Y, when engineered into an E13;A20 fusion variant. Lastly, X-396 displayed synergistic growth inhibitory activity when combined with the mTOR inhibitor rapamycin. Our findings offer preclinical proof-of-concept for use of these novel agents to improve therapeutic outcomes of patients with mutant ALK-driven malignancies.
Introduction
The anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that is aberrant in a variety of malignancies. ALK was originally discovered in anaplastic large cell lymphoma (ALCL) as part of a chromosomal translocation t (2, 5) , which fuses the Cterminal kinase domain of ALK encoded on chromosome 2p23 to the N-terminus of nucleophosmin (NPM) on chromosome 5q35 (1) . Subsequently, a variety of ALK fusion proteins have been found in multiple malignancies, including inflammatory myofibroblastic tumor (IMT) (2) and non-small cell lung cancer (NSCLC) (3) (4) (5) (6) (7) (8) (9) (10) . All ALK fusions tested biologically to date have demonstrated gain of function properties (1, 3, 4, 7) . Activating mutations in wild-type ALK have also been identified in both familial and sporadic neuroblastoma. Most of these activating mutations occur within the tyrosine kinase domain and are transforming in vitro and in vivo (11) (12) (13) (14) .
Importantly, the activity of cancer-specific ALK variants is required for tumor maintenance. Thus, ALK mutants can serve as 'Achilles heels' to be exploited therapeutically. Multiple preclinical studies have shown that specific small molecule ALK tyrosine kinase inhibitors (TKIs) can delay tumor growth and/or induce tumor regression in xenograft and transgenic models (3) (4) (5) (15) (16) (17) (18) (19) .
Based on such promising pre-clinical studies, ALK inhibitors have recently entered into clinical trials. The first agent in humans is PF-02341066 (crizotinib, Pfizer; hereafter referred to as 'PF-1066'), an orally available small molecule ATP-mimetic compound. PF-1066 was originally designed as a MET inhibitor but was recognized to have 'off-target' anti-ALK activity (17) . Strikingly, in a phase I study, patients with ALK fusion positive NSCLC demonstrated a 57% radiographic response rate (20) . By contrast, chemotherapy response rates are <10% in previously treated patients with unselected NSCLC (21). A Phase III trial randomizing patients to crizotinib (PF-1066) vs. standard chemotherapy after disease progression on first-line treatment is now ongoing for patients with ALK fusion positive NSCLC.
Here, we report identification of X-376 and X-396, novel, more potent and specific ALK TKIs with potential therapeutic relevance. We compare the effectiveness of these 'second-generation' TKIs versus PF-1066 both in vitro and in vivo. We demonstrate the anti-tumor activity of these compounds against multiple ALK variants found in NSCLC, including two point mutations in the ALK tyrosine kinase domain which have been associated with acquired resistance to PF-1066. Finally, we show that these ALK TKIs display synergistic anti-tumor activity when combined with the mTOR inhibitor, rapamycin. Lysates were subjected to SDS-PAGE followed by blotting with the indicated antibodies and detection by Western Lightening ECL reagent (PerkinElmer, Waltham, MA). Images were quantified using a Bio-Rad Gel Doc XR and Image Lab software (Bio-Rad, Hercules, CA).
Cell Viability and apoptosis assay. For viability experiments, cells were seeded in 96-well plates at 25%-33% confluency and exposed to drugs alone or in combination the following day. At 72 hours post drug addition, Cell Titer Blue Reagent (Promega, Madison, WI) was added and fluorescence was measured on a Spectramax spectrophotometer (Molecular Devices, Sunnyvale, CA) according to the manufacturer's instructions. All experimental points were set up in hextuplicate replicates and were performed at least two independent times. IC 50 's were calculated using GraphPad Prism version 5 for Windows. The curves were fit using a nonlinear regression model with a log (inhibitor) vs. response formula. For apoptosis experiments, cells were seeded in 12 well plates at 25% confluency and treated in triplicate with ALK TKI. At 72h post drug addition, cells were collected, washed in PBS, and stained with annexin V and propidium iodide according to the manufacturer's instructions (Vybrant Apoptosis Assay Kit, Invitrogen, Carlsbad, CA). Data were collected on a FACSCanto II (BD Biosciences, San Jose, CA) and processed using WinList flow cytometry analysis software (Verity Software, Topsham, ME).
Expression constructs. cDNAs for EML4-ALK E13;A20 (variant 1), EML4-ALK E20;A20 (variant 2), EML4-ALK E6b;A20 (variant 3b), and KIF5B-ALK were synthesized by Geneart (Regensburg, Germany). The cDNAs were subcloned into a 3Flag-CMV vector (Sigma-Aldrich, St. Louis, MO). The L1196M and C1156Y mutations were introduced into the cDNA encoding the E13;A20 variant using site-directed mutagenesis (Stratagene, La Jolla, CA) with mutant specific primers according to the manufacturer's instructions. The cDNAs were fully re-sequenced in each case to ensure that no additional mutations were introduced. A cDNA encoding MET was obtained from Origene (Rockville, MD). Lovly et al page 10 an average volume of 290mm 3 , mice were randomized and dosed via oral gavage with either PF-1066, X-376, or X-396 at the indicated doses. A uniform volume for administration (200μl) was used for each group. Mice were observed daily throughout the treatment period for signs of morbidity/mortality. Tumors were measured twice weekly using calipers, and volume was calculated using the formula: length x width 2 × 0.52. Body weight was also assessed twice weekly. The experiment was terminated after 3 weeks of treatment. Tumor samples were collected at either 2 or 8 hours after the last treatment. Each sample was cut in halves; half was preserved in 10% neutral buffered formalin and half was flash frozen in liquid nitrogen and stored at -80°C.
Pharmacokinetic and toxicity studies. Nude mice (nu/nu; Harlan Laboratories) were injected with H3122 cells as above. Once tumors reached an average volume of 450 mm 3 , a total of 27 athymic mice harboring H3122 tumors were randomized and dosed via oral gavage with either 50mg/kg X-376, 25mg/kg X-396, or the control vehicle. Two, five, and fifteen hours after the single treatment (3 tumors/timepoint/group), mice were sacrificed and serum was collected for assessment of drug concentration using an LC-MS based bioanalytical method by the DMPK group of the Scripps Research Institute (Jupiter, Florida).
To determine if PF-1066, X-376 and X-396 can cross the blood-brain-barrier (BBB), each compound was dosed to three male C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) at their respective efficacious doses (PF-1066: 50mg/kg, X-376 50mg/kg, and X-396 25mg/kg). Two hours after dosing, mice were sacrificed.
Blood and brain tissues were collected and analyzed for drug concentration. The 
Results
X-376 and X-396 are aminopyridazine-based kinase inhibitors with increased in vitro potency against ALK compared to PF-1066. Based upon protein structure modeling of ALK, we designed a series of small molecule inhibitors that we hypothesized would have greater potency and specificity against ALK. While PF-1066 is an aminopyridine-based small molecule inhibitor, the lead compounds we identified, X-376 and X-396, are aminopyridazine-based structures. These agents all share a common hydrophobic 2,6-dichloro-3-fluoro-phenylethoxy group as well as a similar kinase hinge binding group compared to PF-1066, but differ significantly in their side chains (Fig. 1A) . We next performed KINOMEscan (Ambit Biosciences) analysis to test the specificity of the ALK TKIs. Briefly, KINOMEscan is a competition binding assay that quantitatively measures the ability of a test compound to compete with an immobilized, active-site directed ligand (22, 23). Initial KINOMEscan screens on racemic forms of PF-1066 and X-376 showed different but overlapping binding constant specificity profiles (Fig. 1B) . Table S1 summarizes the differential ability of these agents to inhibit the activity of 96 kinases; the vast majority of kinases are minimally affected. Additional Ambit-based dose-response profiling suggested that X-376 and X-396 were approximately 10-fold more potent against ALK but less specific for MET compared to PF-1066 (Table 1 ) (17) .
To attempt to explain the increased potency for X-376 and X-396 against ALK on a structural level, we generated a model of X-376 within the ATP binding pocket of the ALK tyrosine kinase domain (Fig. 1C and 1D structure of PF-1066 in the MET kinase domain (PDB code: 2WGJ). The hydrophobic interaction, especially the aromatic stacking, between Y1269 and the dichloroflorophenyl moiety, is conserved between PF-1066 and X-376 (Fig. 1D) .
However, for hydrogen bonds with hinge residues (E1197 and M1199), X-376 may be (Table S1 ). However, we found HCC78 cells to be only modestly sensitive to PF- We also compared the efficacy of PF-1066 and X-396 to TAE-684 in H3122 cells.
Unlike PF-1066 and X-396, TAE-684 has a diaminophenylpyrimidine scaffold and inhibits ALK, IGF-1R, and IR in biochemical assay (16) . As previously reported in the literature, TAE-684 is a potent inhibitor of H3122 cell growth (5) with an IC 50 of 5nM (Figs. S1E). However, this compound is not in clinical development.
To confirm the target specificity of X-376 and X-396, we assessed the ability of the compounds to inhibit ALK kinase activity using auto-phosphorylation of an ALK We further evaluated the effects of PF-1066 and X-396 on endogenous ALK phosphorylation and potential downstream signaling pathways in H3122 lung cancer cells harboring the EML4-ALK E13;A20 fusion. Compared to PF-1066, X-396 inhibited ALK phosphorylation at lower concentrations of drug (Fig. 2G ). This was accompanied by corresponding inhibition of the downstream targets, ERK and AKT. We also found that phosphorylation of the mTOR substrate, ribosomal protein S6, was inhibited with ALK TKI treatment (Fig. 2G) . Collectively, these data show that X-376 and X-396 are more potent ALK inhibitors than PF-1066.
X-376 and X-396 display less activity against MET than PF-1066. PF-1066 has
higher binding affinity for MET versus ALK in Ambit KINOMEscan assays (17) . By contrast, X-376 and X-396 displayed similar binding constants for both kinases (Table   1 ). To assess if such differences in binding correlated with less activity against MET in cells, we determined the ability of X-376 and X-396 to inhibit the growth of MKN-45 gastric carcinoma cells, which are known to be highly sensitive to MET inhibitors (27).
Compared to X-376 and X-396, PF-1066 was 3 fold more potent against MKN-45 cells (IC 50 s: PF-1066 51nM, X-376 150nM, X-396 156nM) ( Fig. S2A and Table 2 ).
Consistent with these data, PF-1066 more effectively reduced MET autophosphorylation in surrogate kinase assays (Fig. S2B) . Thus, X-376 and X-396 are both more potent and more specific inhibitors of ALK compared to PF-1066. Antitumor activity and pharmacokinetic properties of X-376 and X-396 in vivo. We next examined the effects of X-376 and X-396 in vivo against H3122 xenografts. A pharmacokinetic study revealed that both X-376 and X-396 showed substantial bioavailability and moderate half-lives in vivo (Table S2 ). Based on these data, we selected twice a day dosing for initial efficacy studies. We treated nude mice harboring H3122 xenografts with either X-376 at 50mg/kg bid or X-396 at 25mg/kg bid. Both agents significantly delayed the growth of tumors compared to vehicle alone (Fig. 3A) .
The efficacy was similar to that seen with PF-1066 dosed at 50mg/kg BID (Fig. S3) .
Additional doses and schedules of X-376 and X- 396 have not yet been examined.
However, based on our toxicity studies (below), we show that X-396 dosed at 25mg/kg is probably well below the maximum tolerated dose, suggesting that higher doses and greater efficacy can be achieved.
At the doses used in these xenograft experiments (PF-1066: 50mg/kg bid; X376: 50mg/kg bid; X-396 25mg/kg bid), plasma levels inversely correlated with cellular potency. For example, although PF-1066 and X-396 were the least and most potent ALK inhibitors, respectively, the plasma level at 2 hours after dosing was highest for PF-1066 (10.19 µM), lower for X-376 (6.27 µM), and lowest for X-396 (2.28 µM) (Table S2 ).
The plasma levels followed the same trend at five and fifteen hours after dosing, respectively. These findings suggest that inhibitors like PF-1066 may need to be administered at higher doses in order to achieve the same efficacy of the more potent compounds.
In the xenograft experiments, both X-376 and X-396 appeared well-tolerated in vivo. Mouse weight was unaffected by either treatment (Fig. 3B) . Drug-treated mice in SD rats, all animals survived to study termination. The no significant toxicity (NST) levels were determined to be 50 mg/kg for X-376 and 80mg/kg for X-396. The only statistically significant observation at NST levels was a <50% increase of the liver enzymes, AST and ALT. At NST levels, X-376 achieved an AUC of 41µM.hr and a Cmax of 5.04 µM, while X-396 had an AUC of 66 µM.hr and a Cmax of 7.19 µM (Table   S2 ). These Cmax values are >50 and >400 times the drugs' respective IC 50 's for H3122 cell growth inhibition. Notably, PF-1066 at the selected (tolerated) phase 3 dose results in a plasma level (~500nM at 250mg BID) (32) that is only ~3 times its IC 50 . The NST Cmax value of X-396 also compares favorably with the 2 hour plasma levels required for efficacy in mice (7.19µM vs. 2.28µM, Table S2 ). Taken together, these data suggest that X-396 is able to inhibit ALK effectively at doses far below those that are well tolerated.
Penetration of ALK TKIs in the brain. In EGFR mutant lung cancer, patients with acquired resistance to EGFR TKIs may relapse in the brain. One contributing factor is that the dose of drug in the brain is only one hundredth that in the blood (33). In anticipation of a similar phenomenon occurring in patients with ALK fusion positive lung cancers treated with ALK TKIs, we examined the penetration of PF-1066, X-376, and X-396 across the blood-brain-barrier (BBB) in mice. Each drug was dosed to three male 
C57BL/6J mice at their respective efficacious doses (PF-1066: 50mg/kg, X-376 50mg/kg, and X-396 25mg/kg). Two hours after dosing, mice were sacrificed. Blood and brain tissues were collected and analyzed for drug concentration. Brain penetration was defined as the ratio of compound concentration in brain tissues compared to that in plasma. We found that X-396 had comparable brain penetration to PF-1066, while X-376 had less (Table S3 ). Since PF-1066 at the selected Phase 3 dose achieves a plasma level of ~500nM (32), projection of results from this animal study to humans would suggest that the concentration of PF-1066 in human brain would be only ~80nM (16% of plasma level), which is below the IC 50 (180nM) for inhibiting H3122 cell growth (Table S4) . By contrast, if X-396 were also to achieve a plasma level of ~500nM in humans, its brain concentration would be about 65nM (13% of plasma level), which is significantly higher than its IC 50 of 15nM (Table S4 ). These data suggest that drugs like X-396 could lead to higher efficacy against ALK-fusion positive brain metastases.
However, further studies with additional sampling times will be required to most accurately assess intracranial drug levels. (variant 3b) (6, 34), and KIF5B-ALK. After treatment with X-376, cell extracts were subjected to immunoblotting with antibodies against phospho-ALK and Flag. All fusions displayed dose-dependent inhibition of ALK kinase activity (Fig. 4A) . Based upon quantitative examination of the immunoblotting results (data not shown), no major differences in sensitivity were observed among the four variants in these in vitro surrogate-kinase assays. However, additional studies in cell lines where these ALK variants are the oncogenic 'drivers' are needed to establish more subtle differences.
We next examined the efficacy of X-396 against two point mutations in EML4-ALK recently identified in patients with acquired resistance to PF-1066, L1196M and C1156Y (35). L1196 of ALK corresponds to the "gatekeeper" site, and C1156 is positioned adjacent to the N-terminal helix αC (35). To determine how the L1196M and C1156Y mutations affect ALK fusion proteins, we individually introduced the specific mutations into EML4-ALK E13;A20 cDNAs and performed surrogate kinase assays as described above. Introduction of L1196M and C1156Y into the EML4-ALK fusion protein led to a greater baseline level of phosphorylation (Figs. 4B and 4C) , suggesting that these mutations lead to increased kinase activity. As expected, the L1196M and C1156Y mutants did reduce the sensitivity of the wildtype ALK fusion protein to both PF-1066 and X-396, however, the degree of reduction was less for X-396. 
To expand on these results from the surrogate kinase assays, we evaluated the biological impact of each mutation on drug sensitivity in Ba/F3 cells. Expression of EML4-ALK E13;A20 WT, L1196M, and C1156Y (Fig. 4E ) each led to IL3 independent growth of Ba/F3 cells. In accord with our data above from tumor cell lines with ALK genomic alterations, X-396 was ~10 fold more potent than PF-1066 in inhibiting the growth of Ba/F3 cells expressing EML4-ALK E13;A20 wild-type (IC 50 for WT: PF-1066 250nM, X-396 22nM, Fig. 4E, Table 2 ). As expected, the presence of the L1196M and C1156Y point mutants reduced the sensitivity of the EML4-ALK fusion to both PF-1066 and X-396 (Fig. 4E) . However, the IC 50 values for X-396 against the L1196M and C1156Y mutants were still in the ~100nM or less range (IC 50 for L1196M: PF-1066 1815nM, X-396 106nM; IC 50 for C1156Y: PF-1066 458nM, X-396 48nM, Fig. 4E , Table   2 ). Since the therapeutic window is greater for X-396, these data suggest that X-396 has the potential to overcome these second-site drug resistance mutants.
Combined ALK/mTOR inhibition enhances growth inhibition of ALK fusion
positive lung cancer cell lines. As shown above, treatment of H3122 cells with ALK TKIs led to a decrease in phosphorylation of the mTOR substrate, ribosomal protein S6 (Fig. 2G) . Previous studies in NPM-ALK positive lymphoma cell lines have shown that the mTOR inhibitor, rapamycin, decreases proliferation and increases apoptosis in ALK fusion positive lymphoma cells (36) . Given these two observations, we sought to determine if mTOR inhibition could synergize with ALK inhibition in EML4-ALK fusion positive NSCLC cell lines. Rapamycin alone caused a small but reproducible decrease in the proliferation of H3122 and H2228 cells (Fig. S4) . Strikingly, when rapamycin was combined with X-396, we observed a synergistic decrease of cell growth in both H3122 (Fig. 5A) and in H2228 (Fig. 5B) cells. Drug synergism was assessed by both the Chou-Talalay and Mix-Low Methods (Table S5 and Fig. S5) (37, 38) . Consistent with these data, phosphorylation of the mTOR substrate, S6, was decreased in the presence of rapamycin and was further diminished in the presence of both rapamycin and X-396 (Fig.5C) . Overall, these data suggest that co-treatment with ALK and mTOR inhibitors may represent a strategy to increase the therapeutic efficacy for patients with ALK fusion positive lung cancer. (35). The structural mechanism for how mutation at this site confers resistance to ALK TKIs remains to be elucidated. When the ALK L1196M and C1156Y mutations were introduced into the EML4-ALK E13;A20 fusion, kinase activity, as assessed by ALK autophosphorylation, was not inhibited by up to 300nM of PF-1066. By contrast, ALK autophosphorylation was significantly diminished by X-396, albeit at higher concentrations required to block autophosphorylation of the wild-type fusion. These results were recapitulated in Ba/F3 cells where introduction of the L1196M and C1156Y point mutants reduced the sensitivity of cells to both PF-1066 and X-396, however, the IC 50 values for X-396 against these mutants were still ~100nM or less.
Since both of these point mutations have been found in clinical samples from patients with acquired resistance to ALK TKIs, treatment with X-396 may represent one strategy to overcome them. In addition, our brain drug penetration studies suggest that X-396 can achieve high enough concentrations to treat intra-cerebral metastases effectively should they arise in patients. CAN-10-3879 inhibitor was not evaluated. Our results demonstrate that this combination can synergistically decrease cell proliferation in two different EML4-ALK lung cancer cell lines. These data indicate that mTOR signaling may play critical roles in ALK fusion signaling in general, which is currently not well characterized. Clinically, these data also suggest that trials of ALK TKIs in combination with rapamycin or analogous agents should be considered to enhance the antitumor efficacy of ALK inhibitors. 
